PF-06826647

• CAT Number: I034503
• CAS Number: 2127109-84-4
• Molecular Formula: C20H17N9
• Molecular Weight: 383.42
• Purity: 98%
• Synonyms: PF-06826647; PF 06826647; PF06826647; PF-6826647; PF 6826647; PF6826647; Tyk2-IN-8; Tyk2-IN 8; Tyk2-IN8
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile
• InChI: InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3
• InChIKey: XPLZTJWZDBFWDE-UHFFFAOYSA-N
• SMILES: CN1C=C(C=N1)C2=CN3C(=CC=N3)C(=N2)C4=CN(N=C4)C5(CC(C5)C#N)CC#N

PF-06826647（Cat No.:I034503）is a selective small molecule inhibitor of the enzyme Bruton’s tyrosine kinase (BTK), which plays a crucial role in B-cell receptor signaling and immune cell activation. By inhibiting BTK, PF-06826647 aims to modulate the immune response, particularly in autoimmune diseases and certain cancers, such as B-cell malignancies like lymphoma and leukemia. Its targeted action on the BTK pathway has shown promise in preclinical and clinical studies, with potential therapeutic applications in inflammatory conditions like rheumatoid arthritis and chronic lymphocytic leukemia (CLL). Further clinical trials are needed to establish its safety and efficacy.